Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer research: Open ambition.

× No keyword cloud information.

7 in total

1. BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors: Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal: Cell Date: 2011-09-01 Impact factor: 41.582

2. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Authors: Camellia Banerjee; Nancie Archin; Daniel Michaels; Anna C Belkina; Gerald V Denis; James Bradner; Paola Sebastiani; David M Margolis; Monty Montano
Journal: J Leukoc Biol Date: 2012-07-16 Impact factor: 4.962

3. Suppression of inflammation by a synthetic histone mimic.

Authors: Edwige Nicodeme; Kate L Jeffrey; Uwe Schaefer; Soren Beinke; Scott Dewell; Chun-Wa Chung; Rohit Chandwani; Ivan Marazzi; Paul Wilson; Hervé Coste; Julia White; Jorge Kirilovsky; Charles M Rice; Jose M Lora; Rab K Prinjha; Kevin Lee; Alexander Tarakhovsky
Journal: Nature Date: 2010-11-10 Impact factor: 49.962

4. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.

Authors: Christopher A French; Isao Miyoshi; Ichiro Kubonishi; Holcombe E Grier; Antonio R Perez-Atayde; Jonathan A Fletcher
Journal: Cancer Res Date: 2003-01-15 Impact factor: 12.701

5. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.

Authors: Johannes Zuber; Junwei Shi; Eric Wang; Amy R Rappaport; Harald Herrmann; Edward A Sison; Daniel Magoon; Jun Qi; Katharina Blatt; Mark Wunderlich; Meredith J Taylor; Christopher Johns; Agustin Chicas; James C Mulloy; Scott C Kogan; Patrick Brown; Peter Valent; James E Bradner; Scott W Lowe; Christopher R Vakoc
Journal: Nature Date: 2011-08-03 Impact factor: 49.962

6. RNA polymerase II stalling promotes nucleosome occlusion and pTEFb recruitment to drive immortalization by Epstein-Barr virus.

Authors: Richard D Palermo; Helen M Webb; Michelle J West
Journal: PLoS Pathog Date: 2011-10-27 Impact factor: 6.823

7. Selective inhibition of BET bromodomains.

Authors: Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal: Nature Date: 2010-09-24 Impact factor: 49.962

7 in total

4 in total

Cancer research: Open ambition.

1. BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

2. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

3. Suppression of inflammation by a synthetic histone mimic.

4. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.

5. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.

6. RNA polymerase II stalling promotes nucleosome occlusion and pTEFb recruitment to drive immortalization by Epstein-Barr virus.

7. Selective inhibition of BET bromodomains.

1. PARP1 and CBP lose their footing in cancer.

2. Structural genomics: Open collaboration is key to new drugs.

3. Open data in drug discovery and development: lessons from malaria.

Review 4. Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases.